Close
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatme Jun 2, 2024 09:41PM

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, announced that the clinical data of a randomized controlled Phase 1b study evaluating IBI310 (anti-CTLA-4 monoclonal antibody) in combination with... (continue reading...)


Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer a Jun 2, 2024 09:30PM

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, delivered two oral presentations of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (R&D code: IBI389) for the treatment of... (continue reading...)


China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University Jun 2, 2024 09:19PM

Wistron and imedtac jointly promote leading medical products with CMUH in Malaysia

TAICHUNG, Taiwan, June 2, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH, Taiwan) and the Malaysian International Medical University (IMU), the first and top private medical and health science university in Malaysia, jointly signed a memorandum of understanding (MOU) on international development in May. The MOU will provide a platform to train medical personnel and... (continue reading...)


Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis Jun 2, 2024 09:14PM

CHENGDU, China, June 2, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis (AD) has been released by way of oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. The data of long-term treatment with stapokibart demonstrated sustained efficacy and... (continue reading...)


TECNO exhibits its diverse smartphone and AIoT ecosystem with futuristic AR and AI products at COMPUTEX Taipei 2024, with the concept "Smart of Creation" Jun 2, 2024 09:00PM

TAIPEI, June 2, 2024 /PRNewswire/ -- Innovative technology brand TECNO, has announced its debut at Computex Taipei 2024. At the event, TECNO will showcase its complete lineup of smartphone products and AIoT products under the theme "Smart of Creation." This marks a significant milestone for TECNO as it expands its brand presence in Asia. Among the highlights are the MEGABOOK Series laptops, innovative Mini PCs, the world's smallest AR PC, Pocket Go, and the seamless... (continue reading...)


More PRNewswire

View Older Stories

Jun 2, 2024 09:00PM MSI Unveils New AI and Computing Platforms with 4th Gen AMD EPYC™ Processors at Computex 2024
Jun 2, 2024 06:15PM Fast Guard Service Shares Their Experience with Local Business Owner as the Best Security Guard Company in California
Jun 2, 2024 06:01PM One in Five European Companies Are Facing Strong Pressure to Transform to Stay Viable
Jun 2, 2024 04:00PM FrogData Unveils Major AI Factory Upgrade to Revolutionize Automotive Retail Operations
Jun 2, 2024 03:45PM izmostock Unveils Revolutionary Image Solution for Leasing Industry, Driving Unparalleled ROI and User Engagement
Jun 2, 2024 12:40PM GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology
Jun 2, 2024 12:30PM Miami Beach Inspires this Summer with Film, Fashion and Music Experiences
Jun 2, 2024 11:32AM Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479
Jun 2, 2024 11:24AM Discovery of World War II fighter plane sets path for first U.S.-Papua New Guinea Sister City
Jun 2, 2024 11:00AM Linker Vision to Accelerate Vision AI Adoption Across Enterprise Applications with Large Vision Models, in Collaboration with NVIDIA
Jun 2, 2024 10:45AM ConcertAI to Advance Translational and Clinical Development Solutions in Collaboration with NVIDIA
Jun 2, 2024 10:25AM ASRock Rack Launches New Servers Supporting the NVIDIA Blackwell Architecture at COMPUTEX 2024
Jun 2, 2024 10:00AM MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer
Jun 2, 2024 10:00AM Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC)
Jun 2, 2024 09:43AM Federal Government Authorizes Institute of Information Management to Certify Data Protection Professionals in Nigeria
Jun 2, 2024 09:30AM Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care
Jun 2, 2024 08:42AM Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 2, 2024 08:30AM Trend Micro to Secure AI-Enabled Private Data Centers Worldwide
Jun 2, 2024 08:30AM Vention to democratize industrial automation using NVIDIA AI technologies
Jun 2, 2024 08:00AM OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
Jun 2, 2024 07:00AM Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service
Jun 2, 2024 06:18AM Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Jun 2, 2024 01:13AM Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
Jun 1, 2024 11:56PM Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
Jun 1, 2024 08:25PM Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
Jun 1, 2024 08:17PM CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
Jun 1, 2024 08:00PM Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
Jun 1, 2024 08:00PM Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
Jun 1, 2024 08:00PM Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
Jun 1, 2024 07:13PM GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a La
Jun 1, 2024 06:09PM LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
Jun 1, 2024 05:52PM Sun Bum Makes SPF Waves in Miami with its Largest Ever Beach Hangout for Skin Cancer Awareness Month
Jun 1, 2024 04:30PM Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
Jun 1, 2024 03:40PM BIOHACKING CONFERENCE ANNOUNCES STEMREGENⓇ WILL RETURN AS TITLE SPONSOR FOR 2025
Jun 1, 2024 03:00PM Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
Jun 1, 2024 01:45PM Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Upd
Jun 1, 2024 01:42PM Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
Jun 1, 2024 01:10PM Taseko Announces that Operations at its Gibraltar Mine have been Suspended
Jun 1, 2024 01:01PM PHILADELPHIA KICKS OFF PRIDE MONTH BY SETTING THE FIRST-EVER GUINNESS WORLD RECORDS™ FOR THE "LARGEST ATTENDANCE AT DRAG QUEEN STORY TIME"
Jun 1, 2024 11:40AM Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling!
Jun 1, 2024 11:00AM ICECO Launches APL35 on Indiegogo - The World's Lightest Aluminum Dual-Zone Freezer
Jun 1, 2024 10:00AM Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple
Jun 1, 2024 09:00AM American Cancer Society and American Society of Clinical Oncology Unite to Create One of the Largest and Most Comprehensive Online Sources of Credible Cancer Information
Jun 1, 2024 09:00AM Beverly Hills MD Celebrates Its 10th Anniversary
Jun 1, 2024 09:00AM Hyundai Motor America Reports May 2024 Sales
Jun 1, 2024 09:00AM Vincent Todd Announces the Introduction of Todd Agriscience
Jun 1, 2024 08:05AM Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
Jun 1, 2024 08:00AM Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
Jun 1, 2024 08:00AM BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
Jun 1, 2024 08:00AM Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
View Older Stories